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Abstract 
During the last few years, for therapeutic purposes in oncology, considerable attention has been focused 
on a method called magnetic fluid hyperthermia (MFH) based on local heating of tumor cells. In this paper, 
an innovative, promising nanomaterial, M48 composed of iron oxide-based phases has been tested. M48 
shows self-regulating temperature due to the observable second order magnetic phase transition from 
ferromagnetic to paramagnetic state. A specific hydrophilic coating based on both citrate ions and glucose 
molecules allows high biocompatibility of the nanomaterial in biological matrices and its use in vivo. MFH 
mediator efficiency is demonstrated in vitro and in vivo in breast cancer cells and tumors, confirming 
excellent features for biomedical application. The temperature increase, up to the Curie temperature, 
gives rise to a phase transition from ferromagnetic to paramagnetic state, promoting a shortage of the r2 
transversal relaxivity that allows a switch in the contrast in Magnetic Resonance Imaging (MRI). 
Combining this feature with a competitive high transversal (spin-spin) relaxivity, M48 paves the way for a 
new class of temperature sensitive T2 relaxing contrast agents. Overall, the results obtained in this study 
prepare for a more affordable and tunable heating mechanism preventing the damages of the surrounding 
healthy tissues and, at the same time, allowing monitoring of the temperature reached. 
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Introduction 
Cancer is a serious health issue due to a large 
number of cancer-related human deaths worldwide. 
Nowadays, conventional approaches commonly used 
for cancer treatment include a combination of 
chemotherapy drugs, invasive surgery, guided 
focused ultrasound ablation, thermal ablation, and 
radiation therapy. However, none of these techniques 
is free from risks due to the possible high level of 
toxicity and invasiveness. 
Nanotechnology has provided valuable tools in 
the war against cancer during the last few years, 
including systems for selective drug and gene 
delivery or innovative diagnostic agents [1, 2, 3]. 
Nanotechnology advancements have also made 
possible developing a therapeutic approach named 
Magnetic Fluid Hyperthermia (MFH) based on local 
heating of tumor cells. MFH is considered a 
promising cancer treatment method, known as green 
therapy due to the limited effect on the tumor 
surroundings and relatively low toxicity [4]. MFH is 
currently under testing both in preclinical studies [4, 








gliomas and prostate cancer [7]. This method delivers 
thermal energy to the target region exploiting 
magnetic nanoparticles (NPs) as mediators of heating 
exchange and exposing the tumor to an alternating 
magnetic field (AMF). When magnetic NPs are 
injected in the tumor, and an AMF is applied, tumor 
cells may reach the temperature of 42-46 °C. Such a 
temperature increase is due to the generation of heat 
from magnetic NPs. Magnetic energy is indeed 
dissipated into heat via two different mechanisms 
depending on the size of the magnetic domain of the 
NPs. For a multi-magnetic domains NP, the heating 
effect is due to hysteresis losses. For a single-domain 
NP, it is due to the Brownian-Nèel relaxation 
mechanism. It involves the rapid rotation 
(reorientation) of the magnetic moments within the 
domain of the nanoparticles in the case of Nèel 
relaxation and physical rotation of nanoparticle 
within the fluid in the case of Brownian relaxation 
process in the presence of AMF resulting in an 
extremely selective thermal ablation of the tumor [8]. 
The increase of temperature causes the activation of 
various mechanisms inside the cell such as unfolding 
and denaturation of proteins, necrosis, aggregation, 
apoptosis, and immune response [9], promoted by the 
activation of heat shock proteins and by the 
polarization of tumor-associated macrophages 
gathered by the inflammatory response of the 
surroundings [10]. 
In the last years, numerous research groups 
studied magnetic NPs, such as iron oxides, and 
ferrous fluids that could play a substantial role in 
treating tumors by MFH [11, 12, 13, 14, 15, 16]. A 
widely recognized limitation of this technique is 
represented by the risk of overheating tumor tissue 
that may jeopardize surrounding healthy tissues [17].  
This work aims to test an innovative, 
self-regulating temperature nanomaterial synthesized 
in the form of nanoparticles, hereafter denoted as 
M48. M48 belongs to a class of innovative 
nanomaterials developed by MBN Nanomaterialia 
S.p.A. (Treviso, Italy) that show self-regulating 
temperature [18]. The self-regulating heating effect 
consists of a stable temperature increase of the 
magnetic nanomaterial when exposed to AMF up to a 
maximum value (TSR, Self-Regulating Temperature) 
below the Curie Temperature (Tc). This effect 
provides an intrinsic control for induction heating and 
exploits an efficient energy conversion – from 
electromagnetic energy to heat – regulated by a sharp 
magnetic transition. The values of Tc can be 
modulated by adjusting the composition of the 
nanomaterial itself. The Curie Temperature is 
observed in correspondence to a second-order 
magnetic transition threshold between 
ferromagnetism and paramagnetism. Above Tc, the 
magnetization is negligible and consequently, 
magnetic losses do not occur, switching off the 
heating mechanisms under AMF. The overheating 
phenomenon and the related dangerous effects on the 
healthy surrounding tissues can therefore be avoided 
thanks to the self-regulating properties of the 
maximum temperature level. Such properties are of 
paramount utility when the nanomaterial is 
integrated into biological matrices.  
Moreover, thanks to its magnetic properties, M48 
is a promising contrast agent for Magnetic Resonance 
Imaging (MRI) allowing in principle for simple 
monitoring of hyperthermia treatment and reliable 
control of local temperature distribution in the treated 
tissue. Indeed, considerable interest has been recently 
devoted to temperature-sensitive contrast agents for 
guiding thermal therapies [17, 19]. However, safer 
and more reliable compounds for in vivo theranostic 
methods with low toxicity and tunable temperature 
are highly desirable.  
According to the American Cancer Society, 
breast cancer is the second most common cancer 
worldwide after lung cancer, the fifth most common 
cause of cancer death and the leading cause of cancer 
death in women. Current therapeutic approaches 
include surgery followed by chemotherapy/ 
radiotherapy, an invasive and debilitating approach. 
Novel therapy methods, minimally invasive, and 
devoid of negative impacts, are needed to reduce 
mortality rates in breast cancer patients. In this 
respect, MFH has been proposed as an innovative 
approach to breast cancer treatment [20].  
In this paper, M48 was tested both in vitro and in 
vivo in breast cancer cells and experimental model as 
an efficient MFH heat mediator. An organic coating 
was applied to the prepared iron-based nanomaterials 
to guarantee biocompatibility and stability in 
physiological fluids. The capability to act as 
temperature-sensitive contrast agent for MRI was also 
demonstrated in vitro.  
Methods 
Synthesis of the iron-based NPs 
M48 is synthesized by MBN Nanomaterialia 
S.p.A (Treviso, Italy) using a proprietary 
mechanochemical process [18]. Briefly, M48 was 
prepared from MgO, Fe2O3 and TiO2 powders in 
proportion 2:4:1, performing High Energy Ball Milling 
[21,22] in stainless steel equipment for 6h followed by 
thermal treatment in air at 1200°C for 4h. The 
resulting powder is finely ground by a second ball 
milling step of 1h, then homogeneously dispersed in 
propan-2-ol and processed by ultrasonication to 




promote de-aggregation. Centrifugal classification 
allowed us to extract smaller particles < 200 nm. The 
detailed processing parameters are courtesy of MBN. 
Structural characterization 
For phase analysis, an X-Ray Powder 
Diffractometer (Thermo ARLX’TRA) equipped with a 
Cu-anode X-ray source with a Peltier Si (Li) cooled 
solid state detector was used. The XRPD patterns 
were collected with a scan rate of 0.04°/s, with a 
measurement time of 1.0 s/step. The samples were 
prepared by careful homogenization in a mortar with 
few drops of ethanol. After evaporation of the solvent, 
the sample was deposited on a low background 
sample stage. 
Morphological analysis  
The size and morphology of M48 were 
investigated using Transmission Electron Microscopy 
(TEM, FEI TECNAI G2). For TEM analysis M48 was 
added to the copper grid and desiccated for one day 
before TEM imaging. 
Coating of the iron-based NPs 
The iron-based NPs were coated with citrate 
moieties (using Trisodium Citrate dihydrate 99% Alfa 
Aesar as reagent) and then with glucose (using 
D-(+)-Glucose SigmaUltra 99.5% Sigma as reagent). 
For the coating procedure, a microwave assisted 
synthesis was exploited to significantly reduce the 
reaction time. One mL of M48 suspension 
(concentration of 9.6 mg/mL) and 3.0 mL of sodium 
citrate solution (concentration of 1 M) were added in a 
10 mL glass vial for the microwave assisted reaction, 
using an Anton Paar Monowave 400 microwave 
reactor. The heat treatment followed a general 
literature protocol with some optimizations [23] (heat 
treatment at 90°C for 7 min). The obtained 
nanoparticles were collected by centrifugation at 8000 
rpm for 5 min. The whole procedure was repeated for 
the glucose capping (concentration of the glucose 
starting solution of 1M). At the end of the coating 
procedure, the NPs suspension was dialyzed 
overnight (Spectra/Por 3 Dialysis Membrane 
Standard RC Tubing MWCO: 3.5 kD). Hereafter, the 
citrate and glucose capped NPs will be referred to as 
G-M48.  
Dynamic Light Scattering measurements 
The hydrodynamic size and the zeta potential for 
G-M48 were determined with a Malvern Zetasizer 
Nano instrument. The sample was prepared diluting 
G-M48 water suspension with water (1:5 in volume) 
in a proper plastic cuvette.  
Infrared Spectroscopy 
The organic capping on the M48 surface was 
analyzed by using FTIR spectroscopy, with a JASCO 
FT/IR-660 plus. The sample was prepared by 
dispersing G-M48 in a KBr pellet (3 mg of NPs in 100 
mg of KBr). 
Cytotoxicity assay 
The cytotoxicity of G-M48 was evaluated in two 
cell lines: HeLa and MDA-MB-231 cells, cervix and 
breast cancer cell line respectively (purchased by 
ATCC Manassas, VA). Cells were cultured in 
Dulbecco’s Minimum Essential Medium (DMEM) 
with 10% of Fetal Bovine Serum (FBS), 1% of a mix of 
penicillin/streptomycin 1:1 and 1% of L-glutamine 
200 mM, seeded onto 96-well plates (2500 cells/well) 
and incubated at 37°C in humidified air with 5% CO2 
for 24h. After 24 h, the medium was replaced with 
fresh medium containing 10, 50, 100, 150 ug/ml of 
G-M48.  
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide cytotoxicity assay was 
performed after 2, 24, and 48 h of incubation: 100 µl of 
MTT (at 5 mg/ml concentration, purchased from 
Sigma, Italy) were added to each well and incubated 
for additional 4 h (37°C, 5% CO2). Formazan crystals 
were dissolved in 100 μl of DMSO, and the 
absorbance was read at a wavelength of 570 nm using 
a microplate reader (HTX Microplate Reader BioTek 
Instruments, Winooski, VT, USA). Four 
measurements of optical density (OD) were recorded 
for each sample, and cell viability (%) was calculated 
with the following equation: CV% = (ODsample/ 
ODcontrol) × 100. 
Nanoparticles Internalization in cells: TEM 
analysis  
HeLa and MDA-MB-231 cells were grown as 
monolayers on glass coverslips, treated with 150 
μg/ml of G-M48 for 2, 24 and 48 h at 37 °C, and then 
fixed with 2.5% (v/v) glutaraldehyde and 2% (v/v) 
paraformaldehyde in 0.1 M phosphate buffer, pH 7.4, 
at 4 °C for 1 h. Afterward, cells were post-fixed with 
1% osmium tetroxide and 1.5% potassium 
ferrocyanide for 1 h, dehydrated with acetone and 
embedded in Epon resin. Ultrathin sections were 
stained with lead citrate for 2 min and observed in a 
TECNAI G2 transmission electron microscope (FEI 
Company Italia Srl, Milan, Italy) operating at 80 kV 
and equipped with a Megaview III camera for digital 
image acquisition.  
Magnetic Fluid Hyperthermia 
MFH was performed by using a Nanotherics 
MagneTherm system (Warrington, United Kingdom) 




in water. The heat dissipation value strictly depends 
on the frequency and amplitude of the applied 
alternating magnetic field (AMF). The transformation 
of magnetic energy into thermal energy mediated by 
magnetic nanoparticles in the presence of an external 
AMF is quantified from the value of specific 
absorption rate (SAR). The SAR value of nanoparticles 








Where C is the specific heat capacity of the 
solvent per g, ∆T is the temperature variation in time, 
mFe is the mass of iron in the compound per g [21, 24]. 
The AMF apparatus yields a maximum magnetic 
field intensity of 23 kA/m (≈29 mT). A multichannel 
thermometer equipped with optical fiber probes 
(FOTEMP4, Optocon AG, Germany) was used to 
assess temperature variation within the sample every 
10.0 s. For MFH characterization of G-M48, in order to 
satisfy the Hergt criterion (less rigid than the 
previously published Brezovich one) for the clinical 
translatability of the compound, a frequency f = 473.1 
kHz (0.473 MHz) was coupled with a field strength H 
= 8.75 kA/m [25, 26, 27, 28, 29]. These parameters 
were tested as the most efficient and clinically safe 
among the ones provided by the Magnetherm device, 
providing a coupled H*f = 4.1 109 Am-1s-1 (between 
0.110 and 0.970 MHz and between 1.0 and 23 kA/m ).  
Thermograms of G-M48 were acquired for 
different concentrations (2.5, 3.75, 5, 7.5 and 10 
mg/mL). The multichannel thermometer was placed 
inside the sample during the 20 min acquisition time. 
The time window of 20 min for the effective treatment 
was chosen considering preliminary results and 
experimental conditions suitable for possible 
translatability to the clinics. Preliminary results 
showed that about 15 min were necessary to reach the 
temperature plateau and therefore the total treatment 
time amounted to about 35 min (MFH protocol).  
To maintain cell cultures at 37°C a homemade 
device constituted by a closed box with a 
thermostated air stream was used.  
To avoid contamination of cell cultures, the 
temperature was calibrated before the measurement 
in a disposable sample for each single acquisition. For 
MTT assay, cells were plated on 96 well plates. Cells 
were incubated for 24 hours with 150 µg/mL of 
G-M48 and treated for 35 min with MFH protocol. 
Untreated cells, untreated cells subjected to MFH and 
cells treated with 150 µg/mL of G-M48 but not 
exposed to MFH were used as controls. Twenty-four 
hours after MFH treatment, MTT cytotoxicity assay 
and Hematoxylin and Eosin (H&E) staining were 
performed. For H&E, after the incubation time, cells 
were fixed with 4% buffered formalin solution for 15 
min, rinsed with PBS and then stained with Mayer’s 
hematoxylin (nucleus) and eosin (cytoplasm). Six 
images of each sample were taken at 10X using a 
BX-URA2 Olympus microscope (Olympus Optical, 
GMBH, Hamburg, Germany) equipped with a digital 
camera. MDA-MB-231 cells viability was evaluated 
after one, two, three and four hyperthermia 
treatments and normalized to that of the respective 
control cells. 
Characterization of G-M48 as temperature 
sensitive MRI contrast agent 
MRI was performed using a Bruker Biospin 7T, 
72 mm bore (Bruker Biospin, Ettlingen, Germany) 
scanner to evaluate the in vitro transversal relaxation 
rate (r2 coefficient), the switching contrast ratio 
property and the in vivo biodistribution of G-M48. 
The transversal relaxation times and the 
switching contrast ratio property were measured 
using a standard Spin-Echo Multi-Echo sequence with 
the following parameters: TR = 2000 ms, TE = from 6.5 
to 170.43 ms, FOV = 55 x 55 mm, matrix size = 128 x 
128, slice thickness = 1 mm, number of echoes = 25. 
Transversal relaxation rates (1/T2) were plotted as a 
function of the Fe concentration and r2 relaxivity was 
obtained by the slope of the fitting straight line. To 
characterize the switching contrast ratio property, a 
magnetic field compatible system for the control of 
temperature, from 5°C up to 80 °C, was designed. A 
phantom was prepared with a capillary filled with 
G-M48 (1.9 mg/ml) solution immersed in water and 
settled inside the temperature-controlled box. To 
completely avoid the thermal stretching of the box 
itself, the temperature was slowly increased by 5°C 
every 15 min starting from 25°C.  
To unveil the biodistribution of G-M48 in vivo, 
Balb/c, male mice (n = 3, 6–8 weeks old, Envigo) were 
used. Animals were anesthetized with gas anesthesia 
(a mixture of O2 and air containing 1–1.5% of 
isofluorane), placed in a heated animal bed and 
inserted in a 7.2 cm internal diameter bird-cage coil. 
G-M48 was injected at a dosage of 2 mg Fe/kg. 
T2-weighted images of the mice body were acquired 
using a Rapid Acquisition with Relaxation 
Enhancement (RARE) sequence with the following 
parameters: FOV = 60 x 40 mm, MTX = 256 x 256, slice 
thickness = 1 mm, TE = 33 ms and TR = 2.500 ms. The 
images were acquired before, 40 min, 24 and 72 h after 
G-M48 injection. 
 




Characterization of G-M48 nanoparticles as 
hyperthermia mediators in vivo  
N = 30 nude homozygote female mice (Harlan 
Laboratories, Udine, Italy) were maintained under 
standard environmental conditions (temperature, 
humidity, and 12 h/12 h light/dark cycle, with water 
and food ad libitum) and veterinarian control in the 
animal facility of the University of Verona. Animal 
experiments were conducted following Italian law 
(D.L. 4 March 2014 no. 26) and the European Union 
normative (2010/63/EU).  
Two million MDA-MB-231 cells (human breast 
adenocarcinoma) were injected subcutaneously in the 
flank of nude mice (n = 27). Starting from 15 days after 
cells inoculation, the size of the tumor mass was 
measured every three days by MRI. Three mice did 
not develop tumor and were excluded from the study. 
Twenty-one days post tumor implantation (when 
tumor volume reached about 200 µl) mice were 
divided into three groups according to the treatment. 
Animals in the first group (n = 8, CTRL) received 
saline intratumorally. Animals in the second group (n 
= 8, G-M48) received G-M48 [1.2mg Fe/mL]. Animals 
in the third group (n = 8, G-M48 + MFH) received 
G-M48 [1.2mg Fe/mL] and were exposed to four 
MFH cycles immediately, 24h, 72h and 96h after 
G-M48 injection. In order to improve the homogeneity 
of the distribution of G-M48 within the tumor tissue, 
the total injected volume (100 µl) was divided in 5 
aliquots and injected in different areas of the tumor. 
Each MFH treatment consisted of 35 min application 
(in agreement to the MFH protocol adopted for the in 
vitro study) of an oscillating magnetic field with a 
maximum intensity of 23 kA/m (≈29 mT) and a 
frequency of 473 kHz. In particular, it was chosen the 
same field strength and frequency used for the in vitro 
studies (H = 8.75 kA/m and f = 473.1 kHz). During 
MFH treatments, animals were maintained at 37°C 
using a homemade device constituted by a closed box 
with a thermostated air stream. 
All mice were monitored by MRI before (day 1), 
3 days (day 3) and 6 days (day 6) after the injection of 
G-M48 to monitor the efficacy of treatments. T2 
weighted images were acquired in the axial plane 
using a RARE 3D sequence with TR = 1200 ms, TEeff = 
47.5 ms, NEX = 1, field of view = 25 × 25 × 25 cm3, 
matrix size (MTX) = 256 × 128 × 32, slice thickness = 
0.8 mm, flip angle = 90°, RARE factor = 16. To 
measure the volume of tumors, MR images were 
processed with Paravision software and a 
custom-made MATLAB (MathWorks, Natick, USA) 
script. The tumor area was manually selected slice by 
slice and tumor volume was calculated as (∑ 𝑝𝑢𝑖) ∗𝑛𝑖=1
𝑖𝑚𝑎𝑔𝑒 𝑟𝑒𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛, where pui represents the number of 
pixels manually selected. The percentage increase in 
tumor volume was calculated at each time point as 
100* (Vt-V0)/V0, where Vt is the tumor volume at time 
t and V0 is the initial volume.  
Histology 
Mice were sacrificed and tumor, liver, kidneys 
were dissected out, washed with PBS 0.1 M and fixed 
in 10% formalin for 4 hours. Tissues were embedded 
in paraffin, cut in 5 µm thick sections with a 
microtome and dried at 37°C for 24 h. To evaluate the 
presence of iron in the tissue, Prussian Blue (PB) 
staining was performed: sections were incubated with 
PB solution (5% hydrochloric acid and 5% potassium 
ferrocyanide) for 40 min and counterstained with 
nuclear fast red (Bioptica) for 10 min. Sections were 
examined under a light microscope (Olympus BXS1) 
equipped with a charge-coupled device camera. 
Finally, to evaluate tissue damage in tumor tissue, 
sections were stained with Hematoxylin and Eosin 
(H&E). 
Statistical Analysis 
Statistical analysis was performed using Prism 
software (8.1.1, GraphPad Inc., La Jolla, CA, USA) and 
confirmed by a custom script for statistical analysis 
realized in MATLAB (Mathworks, Natick, MA, USA). 
All the data are expressed as mean ± standard 
deviation of the mean (Mean ± SEM). Statistically 
significant differences were evaluated by TWO-way 
ANOVA with multiple comparisons using the 
Tukey-Kramer method. Differences were considered 
statistically significant when the p-value < 0.05. 
Results and Discussion 
Morphological and structural characterization 
TEM allowed investigation of M48 morphology. 
TEM images, reported in Figure 1 (a,b), reveal that 
M48 nanoparticles have a large size dispersion and 
are present as single nanoparticles or aggregates with 
size ranging from around 10 nm to more than 100 nm. 
A decreased particle size distribution could positively 
affect the in vivo application of M48 nanoparticles. For 
example, reduction of size could affect the 
biodistribution with decreased liver uptake that is 
desirable in the prospective of systemic 
administration. Decreasing particles size could 
however also affect their magnetic properties. When 
the size of the NPs is of the order of the size of 
magnetic domain, there will be a switch to 
superparamagnetic single domain NPs with no 
transition. The optimization of size distribution of the 
magnetic core of the NPs is a very important future 
development of our work and will be the objective of 
further investigations. 





Figure 1. Characterization of M48 and G-M48 nanoparticles. a, b) TEM images of M48; c) XRPD pattern of M48: black line, experimental data; red pattern, Fe3O4 (magnetite, 
COD n.9002319), blue pattern, alpha-Fe2O3 (hematite, COD n.9000139); d) FTIR spectrum of G-M48 (black line); FTIR spectrum of glucose (red line), e) M48 magnetization vs 
temperature; f) Hydrodynamic diameter (by Dynamic Light Scattering) of G-M48. 
 
The composition (both phase and structural 
characterization) of M48 was investigated by the 
XRPD technique. The measured XRPD pattern 
obtained for the M48 sample is shown in Figure 1 (c) 
(black line). A detailed analysis of the experimental 
XRPD pattern revealed that the M48 sample is 
composed by more than one iron oxide compounds. 
This behavior can be observed in Figure 1 (c), where 
the XRPD patterns of 𝛼 -Fe2O3 (hematite, 
Crystallography Open Database (COD) n. 9000139) 
and Fe3O4 (magnetite, COD n. 9002319) are shown in 
blue and red patterns, respectively. From an EDX 
analysis of the M48 sample, also Mg and Ti metals 
were found, and a relative molar ratio Fe:Mg:Ti = 
1:1:0.3 was evaluated. This evidence indicates that 
other iron-containing compounds, as magnesium 
ferrites or iron titanates, that have XRPD patterns 
compatible with the experimental one, can be present 
in the sample. 
Coating of M48 nanoparticles 
To use the sample in biological systems, M48 
NPs were surface coated with glucose molecules and 
citrate ions moieties. The idea of using two 
hydrophilic coating agents was pursued to provide 
high colloidal stability and good biocompatibility of 
the NPs. 
As described in the experimental section, the 
NPs were capped with citrate ions and glucose 
moieties. Citrate capping was chosen as this capping 
enhances the stability of inorganic NPs in water [30]. 
On the other hand, glucose coating was chosen 
considering the pronounced glucose greed of tumor 
cells. Indeed, malignant tumors exhibit a high rate of 
glucose uptake compared to normal cells. Glucose 
molecules are internalized via GLUT transporters, 
highly expressed on the cancer cell surface [31]. For 
this reason, glucose coating is an effective way to 
facilitate the entry of NPs into tumor cells.  




The surface coating was characterized using 
FTIR spectroscopy. Figure 1 (d) shows the FTIR 
spectrum of the citrate and glucose coated M48 
sample (hereafter denoted G-M48) compared with the 
glucose molecule's FTIR spectrum. Several features in 
the FTIR spectrum of G-M48 are due to the glucose 
molecule, confirming that glucose is present on the 
nanoparticles surface. On the other hand, it was 
impossible to distinguish any characteristic band of 
the citrate ions, most probably due to a higher amount 
of glucose than the citrate ions on the nanoparticle 
surface. Figure 1 (d) shows one broadband around 
3300 cm-1 due to -OH stretching of glucose or citrate 
ions and a narrow band around 2900 cm-1 due to -CH 
stretching of the organic backbone. In the region 
between 1600 and 500 cm-1, many vibrations due to 
the glucose molecular skeleton are observed, in 
substantial agreement with those observed for the 
FTIR spectrum of the glucose molecule (red line in 
Figure 1(d)), in the fingerprint region. Besides, an 
absorption band around 570 cm-1 can be assigned to a 
Fe-O vibration of the inorganic phase. 
Colloidal and magnetic properties of water 
dispersion of G-M48 
Dynamic Light Scattering (DLS) was exploited to 
investigate the colloidal stability of water dispersion 
of G-M48 through the measurement of the zeta 
potential. The obtained zeta potential value of –23.2 ± 
10.7 mV, reported in Figure S1, confirms good 
colloidal stability [32].  
The thermomagnetic analysis was performed on 
dry M48 nanoparticles, measuring magnetic 
susceptibility variation with temperature, on-heating 
between -85 and 200 °C, and on-cooling down to 40°C, 
in inert Argon atmosphere, applying a 10 Oe magnetic 
field at 502 Hz. A Curie temperature (Tc) of 95 °C was 
determined as the temperature of susceptibility at half 
height of the curves normalized at the maximum peak 
before susceptibility drop. Indeed, thanks to their 
innovative design and synthesis approach, M48 at low 
temperature is in an ordered state with low entropy, a 
so-called ferromagnetic state, and can undergo a 
second-order phase transition into a paramagnetic 
state at a specific temperature Tc (Tc = 95°C).  
Cytotoxicity and cell internalization 
An important feature for the biomedical 
application of nanoparticles in MFH is the absence of 
cytotoxicity when used without AMF. Cell viability 
was therefore assessed after 2, 24, and 48h of 
incubation with G-M48 in MDA-MB-231 (Figure 2 (a)) 
and HeLa cells (results in supplementary 
information). MTT assay reveals that G-M48 is safe up 
to the concentration of 150 μg/mL for long incubation 
times (48 h, Figure 2 (a)). The electron-dense chemical 
composition of G-M48 allowed to unveil the 
intracellular distribution and the internalization 
process of the nanoparticles in MDA-MB-231 cells 
(Figure 2 (b-f)) at different incubation times. In the 
cytoplasm, G-M48 nanoparticles were always found 
enclosed into endosomes (Figure 2 (c-d), arrowheads) 
and, following the lytic pathways, secondary 
lysosomes/residual bodies (Figure 2 (e), 2 (f), 
asterisks). G-M48 nanoparticles were thus always 
entrapped in vesicular structures and never free in the 
cytoplasm or in contact with any organelle, 
confirming that endocytosis can be identified as the 
primary internalization process in MDA-MB-231 cells. 
Mitochondria, endoplasmic reticulum and Golgi 
complexes preserved their morphology, confirming 
the absence of cell damage or death up to 48 h of 
incubation time.  
In vitro Magnetic Fluid Hyperthermia 
characterization 
Figure 3 (a) reports the thermograms up to the 
plateau collected in aqueous suspensions of G-M48 at 
different concentrations. As expected, an increase in 
NPs concentration (and so in the iron content) 
increases temperature variation. Thermograms were 
collected starting from a specific bulk temperature, in 
this case, 37.0 °C. This starting condition was chosen 
to simulate the condition of in vivo experiments. As 
reported in Figure 3 (a), the most concentrated sample 
reveals a promising increase of temperature of 5.5 ± 
0.5 °C that paves the way to more exciting results in 
vitro and in vivo. For each sample the temperature 
plateau was reached approximately after 15 minutes. 
The SAR of G-M48 was determined in aqueous 
solution from the acquired thermograms, and a value 
of 47.0 ± 8.0 Wg-1 was obtained. SAR depends on 
various parameters such as size, shape, and magnetic 
properties of nanoparticles, frequency, and intensity 
of the applied external AMF [33]. The result agrees 
with typical SAR values reported in the literature for 
iron oxide nanoparticles (ranging from 20 to 400 Wg-1) 
[33, 34].  
As reported in Das et al. 2019 [34], cancer cells 
are more sensitive to temperature enhancement than 
non-tumoral cells, and usually, temperature around 
46 °C can induce death in tumor cells. According to 
literature, MFH involves cancer treatment in a 
temperature range of 40–46 °C, at which denaturation 
and aggregation of intracellular proteins induce cell 
death [35]. 
During the early days of magnetic hyperthermia 
applications for cancer therapy it was commonly used 
the Brezovich criterion in order to identify an upper 
limit to the magnetic field strength and the frequency 




applied in the treatments. This limit was calculated 
through the equation C = H*f (H is the magnetic field 
intensity in Am-1 and f is the frequency of the related 
field in s-1) and it is equal to 4.85 108 Am-1s-1. 
Nowadays it is accepted another safety criterion, the 
so called Hergt criterion. It is a less rigid rule that was 
introduced to adapt the magnetic hyperthermia 
procedure to different geometries and shapes of the 
treated body. It can be summarized as C = H*f ≤ 5.0 
109 Am-1s-1. Considering this rule, the frequency and 
the magnetic field strength were chosen according to 
the Hergt criterion with a final value of C = 4.1 109 
Am-1s-1, perfectly fitting the above condition [29]. 
G-M48 was tested as hyperthermia mediator on 
MDA-MB-231 cells at the concentration of 150 μg/mL, 
verified to be the highest non-toxic concentration 
(Figure 3 (b)). MDA-MB-231 cells were incubated with 
G-M48 for 24h and exposed to four cycles of AMF 
spaced 24h one each other.  
Every effective cycle lasted 20 min (following the 
initial 15 minutes, necessary to reach the temperature 
plateau). Then, cell viability was determined 24h after 
the last hyperthermia treatment and normalized to the 
related control cells, as shown in Figure 3 (b). The 
percentage of cell viability was significantly affected 
by MFH treatment compared to control conditions 
(untreated cells, untreated cells subjected to MFH, 
and cells treated only with G-M48 but not exposed to 
MFH). MDA-MB-231 cells treated only with G-M48 
but not exposed to MFH showed a percentage of 
viability of 95.3 ± 4.3%, while cells treated with G-M48 
and exposed to MFH showed a percentage of viability 
of 73.0 ± 2.5% and 52.0 ± 4.3% after the first and the 
second hyperthermia treatment, respectively. After 
the third and the fourth treatment, the viability 





Figure 2. In vitro viability of MDA-MB-231 cells and G-M48 internalization at TEM. a) MTT assay in MDA-MB-231 cells shows that G-M48 is safe up to a concentration of 150 
μg/mL and up to 48 h of incubation time; the error bar represents SEM over six replicates. Transmission electron microscopy images of G-M48 uptake and distribution in 
MDA-MB-231 cells. b) MDA-MB-231 cells internalize G-M48 via endocytosis (arrow). c-f) G-M48 nanoparticles are compartmentalized into endosomes (arrowheads in c,d) 
distributed in the cytoplasm, as well as in residual bodies (asterisks in e,f). MDA-MB-231 cells show well-structured mitochondria (M) and endoplasmic reticulum cisternae, 
demonstrating no cell damage. N: cell nucleus. 





Figure 3. Viability of MDA-MB-231 after MFH treatments and related histologies of the different groups. a) Thermograms were collected in water solutions at different 
concentrations of G-M48 suspension; b) MTT assay on MDA-MB-231 cells after multiple MFH treatments (each every 24 h). (c-h) Light microscopy images of H&E stained 
MDA-MB-231 cells: c) control cells, d) cells incubated with G-M48 without AMF application, e) f), g), h) Cells incubated with G-M48 and subjected to I, II, III, IV MFH treatments 
and observed 24 hours after the treatment. Scale bar: 50 𝜇m. 





Figure 4. Characterization of G-M48 as temperature sensitive MRI contrast agents. In vivo biodistribution and clearance verified by MRI and histological examination. a) The plot 
of transversal relaxation rate versus Fe concentration in water dispersed G-M48 phantoms, at 25°C. MRI images of phantoms cross section are also reported. b) SNR of G-M48 
water suspension at 25 and 75°C and related magnetization curve of M48. The T2 signal variation has been observed in the related histogram. c-d) MRI images of a phantom 
constituted by a capillary filled with G-M48 (white arrow) and placed inside a thermostated box at 25°C and at 75 °C. MR images of a representative animal acquired using a 
T2-weighted sequence before (e, h), 40 min (f, i) and 72 hours (g, l) after the injection of G-M48. The liver and the kidney are indicated by arrows in Figure 4 (e-h), respectively. 
After 40 min the signal intensity (S.I) in the liver dropped by 32.6% (Figure 4 (f) arrow). In the kidneys, no appreciable loss of signal could be detected 40 min post-injection, while 
at 72 hours the S.I decreased by 45 % (Figure 4 (l)). Prussian Blue staining of liver and kidneys 72h after administration of G-M48 (Figure 4 (m, n), respectively). 
 
Histological examination of MDA-MB-231 cells 
stained with H&E confirmed the results obtained by 
MTT (Figure 3 (c-h)). Cells incubated with G-M48 and 
subjected to AMF demonstrated a more pronounced 
cell death effect after the first (e) and the second (f) 
MFH treatment in comparison with control cells (c) or 
to cells incubated with G-M48 without AMF 
application (d). In agreement with the MTT data, after 
the third and fourth treatment, cell viability 
recovered. The observed recovery effect can be 
partially attributed to cell replication and consequent 
G-M48 dilution. Moreover, it is well-known that 
hyperthermia stress induces the synthesis of a class of 
proteins named ‘heat shock proteins’ (Hsps) [36], 
which may induce thermoresistance with a 
consequent decrease of the efficacy of the last two 
treatments [37, 38, 39].  
Characterization of G-M48 as MRI 
temperature sensitive contrast agent  
The transversal (spin-spin) relaxation time of 
water dispersion containing G-M48 was measured at 
7T in a series of phantoms with variable iron 
concentration (from 0.21mM to 3.47 mM). Values of 
1/T2 vs. Fe concentration were interpolated using a 
straight line whose slope determines the transversal 
relaxivity of the NPs under investigation (Figure 4 
(a)). As shown in the same figure, the T2-weighted MR 
images of G-M48 phantoms tend to become darker 
with increasing iron concentration showing that 
G-M48 can effectively reduce the spin-spin relaxation 
time of water protons as a T2 contrast agent. 
Transversal relaxivity (r2) of 32.10 mM-1 s-1 was 
obtained, comparable to the value of a commercial 




iron oxide MRI contrast agent, like Endorem [35, 36] 
confirming the potential of G-M48 as a contrast agent 
for MRI. 
As reported in Figure 1 (c), the magnetization of 
M48 strongly depends on temperature through a 
second-order magnetic phase transition occurring at 
95°C (Tc). Therefore, a relevant decrease in the 
transversal relaxivity is expected as temperature 
increases. Figure 4 (c, d) shows MR images of a 
phantom containing a G-M48 filled capillary 
embedded in water acquired at 25°C (i.e., well below 
Tc) and at 75°C (i.e., not far from Tc), corresponding to 
the red and green dots respectively in Figure 4 (b). A 
substantial increase in the signal of the G-M48 filled 
capillary is visible. The histogram shows the 
quantitative signal to noise ratio (SNR) of G-M48 
capillary that increases from 21.8 ± 5.4 (T = 25 °C) to 
72.3 ± 2.0 (T = 75°C). This property allows G-M48 to be 
a temperature-sensitive contrast agent. The SNR 
increase could be more relevant if observed at 95°C, 
but the available experimental apparatus could not be 
used at temperatures higher than 75 °C. However, as 
an iron-based contrast agent, it has to be considered 
the well-known issue related to the susceptibility 
artifacts that produces in MRI images “signal voids” 
in large areas surrounding the iron core. High local 
concentrations of NPs, as those used in MFH, may 
therefore destroy the signal of tumor tissue and 
prevent the observation of tumor anatomical details. 
The currently used nanoparticle has a 
ferromagnetic-paramagnetic transition at 95°C, while 
a substantially lower transition temperature (around 
42-45°C) should be necessary for safe and effective 
translation to the clinic. However, the present 
nanoparticle belongs to a class of nanomaterials 
whose transition temperature can be modulated by 
adjusting the composition of the nanomaterial itself. 
The present is a proof-of-concept of the usefulness of 
such materials as temperature sensitive contrast agent 
and future investigations will be devoted to 
preparation and characterization of nanoparticles 
with ferromagnetic-paramagnetic transition occurring 
at lower temperature. 
Finally, the biodistribution and clearance of M48 
nanoparticles were investigated in vivo. G-M48 was 
intravenously injected in healthy mice and monitored 
up to 72h. In Figure 4, MR images of a representative 
mouse acquired using a T2-weighted sequence before 
(e, h), 40 min (f, i), and 72 (g, l) hours after the injection 
of G-M48 are shown. A dosage of 2 mg Fe/kg was 
administered. The signal intensity (S.I) in the liver 
decreased by 32.6 ± 5.2% (Figure 4 (f) arrow) and by 
46.8 ± 3.9% 40 min and 24 h after injection, 
respectively, indicating early hepatic accumulation of 
the nanoparticles. Seventy-two hours after G-M48 
injection, the S.I in the liver dropped by 58.13±4.5% 
(Figure 4 (g)). In the kidney, no appreciable loss of 
signal could be detected 40 min post-injection (p.i.), 
while 72 h p.i. the S.I decreased by 45 ±7.3% as it is 
visible in Figure 4 (l) (asterisk). The loss of S.I in both 
cortex and medulla of the kidney observed 72h p.i. 
may indicate renal clearance of G-M48. No loss of 
signal was detected in the spleen.  
To validate MRI results, histological examination 
was performed. Prussian Blue staining of liver and 
kidneys (see Figure 4 (m, n)) showed several blue 
spots homogeneously distributed in the tissues 
indicating the presence of iron. Of note, the tissues 
exhibit no relevant modifications in the parenchyma 
with good preservation of cellular morphology, as 
shown in Figure 4 (m, n) for liver and kidney, 
respectively, indicating that G-M48 has a good 
biocompatibility. 
Characterization of G-M48 as hyperthermia 
mediators in vivo in an experimental model of 
breast cancer 
The experimental plan illustrated in Figure 5 was 
implemented to test the efficacy of G-M48 as an MFH 




Figure 5. Schematic illustration of the in vivo experiment. 





Figure 6. MRI monitoring of the % of tumor growth and histological examination. Representative MR images of the tumor’s growth for the group administered with saline 
solution (a) and G-M48 + MFH (b). (c) Average tumor volume at different time points after tumor implantation (mean ± SEM). (d) % Tumor growth 3 and 6 days after the first 
MFH treatment (corresponding to 23 and 26 days after tumor implantation, respectively). A TWO-way ANOVA statistical test and a multiple comparison Tukey-Kramer test was 
used to assess the statistical significance of the % Tumor growth. (e-f) Histological slices of tumors treated with G-M48+MFH stained with Prussian Blue (e) and H&E (f). (g-h) 
Histological slices of tumors treated with saline and stained with Prussian Blue (g) and H&E (h). 
 
Twenty-one days after cell implantation (tumor 
volume approximately 200 ul), G-M48 nanoparticles 
were intratumorally injected in mice. Four MFH 
treatments consisting of 20 min of exposure to AMF 
were applied (following the initial 15 minutes, 
necessary to reach the temperature plateau). Figure 6 
(a-b) shows representative MRI images acquired in 
two mice belonging to the CTRL group and the 
G-M48 + MFH group. MRI images clearly show that 
tumor growth is considerably faster in the CTRL 
group than in the treated group. Moreover, the 
presence of G-M48 in the tumor tissue is detectable by 
MRI as signal voids, according to its ability to behave 
as a negative contrast agent (Figure S4, 
supplementary information, shows additional 
images). The tumor volume progression for the three 
experimental groups is reported in Figure 6 (c). The 
tumor volume does not differ among the three groups 
until day 21st after tumor cell implantation, which 
corresponds to day 1 of the treatment. After the 
second MFH cycle (24 hours after the first treatment), 
the tumor volume in G-M48 + MFH mice remains 
substantially lower than in control groups (saline 
solution and G-M48) (Figure 6 (c)). The percentage 
increase of the tumor volume for the experimental 
groups on day 3 and day 6 is shown in Figure 6 (d). 
Values are expressed as percentages of the initial size, 
measured at day 1 of the treatment plan (Figure 5). 
Data are reported as mean ± SEM. On day 3, while the 
tumor volume of group G-M48 + MFH is stable 




(3.45% ± 1.59) compared to the initial volume, the 
tumor volume of CTRL and G-M48 groups strongly 
increases by 91.11% ± 13.50 and 82.67% ± 16.68, 
respectively. At day 6, the tumor volume in the group 
G-M48 + MFH remains significantly smaller (43.47% ± 
17.20) than either the CTRL group (236.09% ± 30.99) or 
the G-M48 group (179.51% ± 46.23), showing that 
G-M48 strongly inhibits tumor growth when applied 
as MFH mediator. It is noteworthy that a small 
difference in % tumor growth was also detected 
between CTRL and G-M48 groups. This may indicate 
marginal toxicity of the nanoparticles themselves that 
was not evidenced in vitro. It has to be considered that 
in vivo fate of injected nanoparticles could differ from 
in vitro: as apparent from MRI, upon intratumoral 
injection, nanoparticles accumulate heterogeneously 
in the tumor mass and, therefore, may give rise to 
local areas of very high concentration and toxicity. 
Future efforts will be devoted to minimizing such 
heterogeneous distribution in tumor tissues to 
optimize toxicity and efficacy.  
The progress of tumor volume reported in 
Figure 6 (c) shows that the highest efficiency (no 
increase of tumor volume) is reached after the second 
MFH treatment in agreement with in vitro cell culture 
studies. Single heat treatment could induce 
irreversible protein damage and result in protein 
aggregation or inhibition of cellular functions. 
Moreover, it is well known that mild hyperthermia 
treatments can induce and regulate apoptosis and 
heat shock proteins (Hsps) expression. The tissue 
level effects include pH changes, alterations in 
perfusion, and oxygenation of the tumor micro- 
environment. To get more insight into cell death 
mechanisms and their dynamics, further studies will 
be needed to identify expression of different 
biomarkers related to necrosis and apoptosis. The 
effectiveness of any hyperthermia treatment greatly 
depends on the temperature generated at the targeted 
sites of action, duration of exposure, and specific 
cancer cells [23, 35, 42, 43].  
At day 6 of the treatment, mice were sacrificed, 
and the tumor masses excised for histological 
analysis. Figure 6 (e-h) shows histological slices of 
tumors treated with G-M48 + MFH and CTRL. 
Prussian Blue staining confirmed the presence of iron 
inside the tumor mass (see blue spots indicated by 
‘NPs’) in the G-M48 + MFH group (e). H&E staining 
revealed damaged regions characterized by a paucity 
of cells distributed in different portions of the tumor 
(Figure 6 (f)) in the G-M48 + MFH group. The saline 
group resulted negative for Prussian Blue staining 
and did not exhibit apparent modifications in the 
parenchyma with good preservation of cellular 
morphology in the core and in the peripheral area of 
the mass (Figure 6 (g-h)). Good preservation of tumor 
tissue with the absence of necrotic areas was detected 
in the G-M48 group whose H&E histological slices 
closely resembled those of the CTRL group (see 
Figure S5).  
Conclusion 
This study characterized an innovative 
nanomaterial, M48, as a theranostic agent, combining 
diagnostic imaging with local treatment of cancerous 
tissues. The results show that a double shell coating 
process makes M48 water-soluble, biocompatible, and 
safe both in vitro and in vivo. T2 weighted MR images 
of G-M48 phantoms performed at 25°C and 75°C 
demonstrate the nanomaterial switching contrast 
property, opening new scenarios in MFH treatments 
controlled by MRI imaging. The biodistribution of 
G-M48 was investigated by MRI: clear and early loss 
of signal was detectable in the liver (40 min p.i.) while 
late loss of signal was detectable in kidneys (72h p.i.).  
Finally, MFH experiments confirm the ability of 
G-M48 to act as a hyperthermia mediator both in vitro 
and in vivo. Results obtained in vivo are particularly 
interesting: after the first two MFH treatments, G-M48 
nanoparticles strongly inhibit tumor growth (% tumor 
growth 3.45% ± 1.59 vs. 91.11% ± 13.50 in the CTRL 
group). 
Overall, our results pave the way for efficient 
and minimally invasive cancer therapy and diagnosis 
by applying a single NP as a hyperthermia heating 
agent and MRI contrast agent with self-regulating 
temperature properties.  
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